Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.35 |
| ▸ | HTR2A | P28223 | 7/20 | 0.35 |
| ▸ | HTR2B | P41595 | 7/20 | 0.35 |
| ▸ | HTR1A | P08908 | 6/20 | 0.35 |
| ▸ | HTR1D | P28221 | 5/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63802 | 0.77 | HTR2C (0.35) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL62903 | 0.74 | MTNR1A (0.33) | MTNR1A | |
| SCHEMBL64338 | 0.73 | — | — | |
| SCHEMBL9283980 | 0.73 | HTR2C (0.34) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL631761 | 0.72 | HTR2C (0.33) | HTR2CHTR2AHTR2BADRA2AADRA2C | |
| SCHEMBL1472895 | 0.72 | HTR2C (0.33) | HTR2CHTR2AHTR2BADRA2AADRA2C | |
| SCHEMBL2486470 | 0.72 | HTR2C (0.33) | HTR2CHTR2AHTR2BADRA2AADRA2C | |
| SCHEMBL1483219 | 0.72 | HTR2C (0.33) | HTR2CHTR2AHTR2BADRA2AADRA2C | |
| SCHEMBL21872053 | 0.69 | HTR2C (0.40) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL21872018 | 0.69 | MTNR1A (0.47) | HTR2CHTR2AHTR2BHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | claimed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | claimed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | claimed |
| EP-2392561-A1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2011-12-07 | — | — | EP | claimed |
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | RHEOGENE, INC. | 2009-04-30 | — | — | US | claimed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| EP-1534658-A4 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1534658-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | claimed |
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-1957496-B1 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1534658-A4 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1534658-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | ESRRB, ESRRA, KDELR1 | HTR2C 4270/4885HTR2A 3752/4885HTR2B 4349/4885 |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | HTR2C 4270/4885HTR2A 3752/4885HTR2B 4349/4885 |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | HTR2C 4270/4885HTR2A 3752/4885HTR2B 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.